Table 2.
Current psoriasis treatments and treatment satisfaction subscale scores.
| Current treatment |
||||||
|---|---|---|---|---|---|---|
| TSQM subscales, median (IQR) | Topical only (N = 295) | Methotrexate (N = 164) | Cyclosporine (N = 18) | Acitretin (N = 36) | Adalimumab (N = 149) | Etanercept (N = 186) |
| Effectiveness | 50 (41.7-66.7) | 66.7 (50-83.3) | 66.7 (50-83.3) | 66.7 (50-83.3) | 83.3 (66.7-100) | 83.3 (66.7-100) |
| Side Effects | 100 (100-100) | 100 (100-100) | 100 (91.7-100) | 100 (91.7-100) | 100 (100-100) | 100 (100-100) |
| Convenience | 66.7 (50-77.8) | 83.3 (66.7-88.9) | 66.7 (61.1-83.3) | 77.8 (66.7-91.7) | 77.8 (66.7-83.3) | 77.8 (66.7-83.3) |
| Overall Satisfaction | 66.7 (50-75) | 75 (66.7-83.3) | 79.2 (50-91.7) | 66.7 (50-83.3) | 83.3 (66.7-91.7) | 83.3 (66.7-91.7) |
| Current treatment |
|||||||
|---|---|---|---|---|---|---|---|
| TSQM subscales, median (IQR) | Infliximab (N = 42) | Ustekinumab (N = 71) | NB UVB (N = 118) | MTX-ADA (N = 48) | MTX-ETA (N = 22) | MTX-INF (N = 33) | P valuea |
| Effectiveness | 83.3 (66.7-100) | 83.3 (50-100) | 75 (58.3-83.3) | 83.3 (66.7-95.8) | 70.8 (58.3-83.3) | 83.3 (66.7-91.7) | < 0.001 |
| Side Effects | 100 (100-100) | 100 (100-100) | 100 (100-100) | 100 (87.5-100) | 100 (91.7-100) | 100 (91.7-100) | 0.001 |
| Convenience | 66.7 (50-88.9) | 83.3 (66.7-94.4) | 72.2 (61.1-83.3) | 83.3 (66.7-83.3) | 72.2 (66.7-83.3) | 72.2 (66.7-83.3) | < 0.001 |
| Overall Satisfaction | 83.3 (66.7-100) | 83.3 (66.7-100) | 83.3 (66.7-91.7) | 83.3 (75-100) | 83.3 (75-83.3) | 83.3 (66.7-91.7) | < 0.001 |
TSQM, Treatment Satisfaction Questionnaire for Medication version II; NB UVB, narrowband ultraviolet B phototherapy; MTX, methotrexate; ADA, adalimumab; ETA, etanercept; INF, infliximab; IQR, interquartile range
a
Kruskal-Wallis test